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Heart Failure
Cardiac G-Protein–Coupled Receptor Kinase 2 Ablation
Induces a Novel Ca2 Handling Phenotype Resistant to
Adverse Alterations and Remodeling After
Myocardial Infarction
Philip W. Raake, MD; Xiaoying Zhang, PhD; Leif E. Vinge, MD, PhD; Henriette Brinks, MD;
Erhe Gao, MD, PhD; Naser Jaleel, MS; Yingxin Li, MS; Mingxin Tang, MS; Patrick Most, MD;
Gerald W. Dorn II, MD; Steven R. Houser, PhD; Hugo A. Katus, MD;
Xiongwen Chen, PhD; Walter J. Koch, PhD
Background—G-protein–coupled receptor kinase 2 (GRK2) is a primary regulator of -adrenergic signaling in the heart.
G-protein–coupled receptor kinase 2 ablation impedes heart failure development, but elucidation of the cellular
mechanisms has not been achieved, and such elucidation is the aim of this study.
Methods and Results—Myocyte contractility, Ca2 handling and excitation-contraction coupling were studied in isolated
cardiomyocytes from wild-type and GRK2 knockout (GRK2KO) mice without (sham) or with myocardial infarction
(MI). In cardiac myocytes isolated from unstressed wild-type and GRK2KO hearts, myocyte contractions and Ca2
transients were similar, but GRK2KO myocytes had lower sarcoplasmic reticulum (SR) Ca2 content because of
increased sodium-Ca2 exchanger activity and inhibited SR Ca2 ATPase by local protein kinase A–mediated
activation of phosphodiesterase 4 resulting in hypophosphorylated phospholamban. This Ca2 handling phenotype is
explained by a higher fractional SR Ca2 release induced by increased L-type Ca2 channel currents. After -adrenergic
stimulation, GRK2KO myocytes revealed significant increases in contractility and Ca2 transients, which were not
mediated through cardiac L-type Ca2 channels but through an increased SR Ca2. Interestingly, post-MI GRK2KO
mice showed better cardiac function than post-MI control mice, which is explained by an improved Ca2 handling
phenotype. The SR Ca2 content was better maintained in post-MI GRK2KO myocytes than in post-MI control
myocytes because of better-maintained L-type Ca2 channel current density and no increase in sodium-Ca2 exchanger
in GRK2KO myocytes. An L-type Ca2 channel blocker, verapamil, reversed some beneficial effects of GRK2KO.
Conclusions—These data argue for novel differential regulation of L-type Ca2 channel currents and SR load by GRK2.
G-protein–coupled receptor kinase 2 ablation represents a novel beneficial Ca2 handling phenotype resisting adverse
remodeling after MI. (Circulation. 2012;125:2108-2118.)
Key Words: calcium  experimental models  heart failure  excitation contraction coupling
 G-Protein coupled receptor kinase 2
Alterations in myocyte contractility and Ca2 cycling arehallmarks of the progression of heart failure (HF). In
failing cardiac myocytes, the sarcoplasmic reticulum (SR)
Ca2 content is decreased and the Ca2 transient is decreased
and prolonged, resulting in depressed myocyte contractility.1
This is generally considered to be a consequence of increased
sodium-Ca2 exchanger (NCX) activity, reduced SR Ca2
ATPase (SERCA) expression and activity (probably due to
decreased phospholamban [PLB] phosphorylation), and in-
creased PLB/ SERCA ATPase ratio, as well as an augmented
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open probability of the ryanodine receptor, causing SR Ca2
leak.2,3 Alterations of the L-type Ca2 channel (LTCC), the
trigger for the Ca2-induced SR Ca2 release, also contribute
to the pathophysiological changes in Ca2 homeostasis in
failing myocytes.4 In addition to these changes causing dys-
functional contractile performance, the rise of diastolic Ca2
may increase the risk of arrhythmias and induce pathological
cardiac remodeling.5
Editorial see p 2054
Clinical Perspective on p 2118
The increased activity of the sympathetic nervous system
associated with HF is a compensation to normalize cardiac
function by enhancing Ca2 cycling and maximize contractile
force through the -adrenergic signaling pathway. In acute
HF, these changes can improve systemic perfusion whereas in
chronic HF the augmentation in catecholamines is associated
with mortality6 and results in a downregulation of
-adrenergic receptors (ARs) promoted by upregulated G
protein–coupled receptor kinase 2 (GRK2). G protein–cou-
pled receptor kinase 2 is the primary GRK in the heart and a
prototype regulator of AR signaling.7 We have previously
identified GRK2 as a culprit in the progression of HF, and
GRK2 inhibition (by expression of its c-terminal domain,
called ARKct) or gene silencing has rescued disparate
models of HF.8–10 Our recent study indicates that the benefits
of ARKct could be related to enhanced myocyte contractil-
ity by increasing LTCC currents and its responsiveness to
-adrenergic agonists.11 However, the exact underlying cel-
lular mechanisms for these beneficial effects in HF after
ARKct expression or GRK2 ablation are not clearly defined.
It is especially important to define these mechanisms because
in light of the recent success of AR blocker therapy in
clinical HF management, the results with ARKct and GRK2
silencing appear paradoxical, as the major function of GRK2
in cardiac myocytes is to dampen AR signaling in a manner
similar to that of AR blockade. We have found that ARKct
expression can cause a molecular remodeling of the cardiac
AR system with receptor upregulation and improved AR
signaling, and a recent study with chronic mediated ARKct
expression in a rat HF model showed that myocardial AR
changes are probably down-stream of neurohormonal lower-
ing including reduction in sympathetic nervous system activ-
ity.12 In this regard, the role of GRK2 inhibition must
mechanistically go beyond resensitizing ARs and fully
understanding GRK2-dependent signaling pathways might
enlighten novel therapeutic targets.
To date, little is known about how GRK2 specifically alters
cardiac myocyte function and Ca2 cycling in normal and
failing cardiac myocytes. The present study was designed to
define the role of GRK2 and GRK2-dependent signaling in
excitation-contraction coupling (ECC) in normal and dis-
eased hearts. We used our previously characterized cardiac-
specific GRK2KO mice10,13 to study myocyte ECC coupling
and Ca2 homeostasis in cardiac myocytes from mice with or
without post-MI ischemic HF. We demonstrate for the first
time that loss of GRK2 induces a distinct Ca2 handling
phenotype: Myocyte contractility and Ca2 handling are
normal even though the SR Ca2 content is reduced because
there is an increase in LTCC activities and resulting increases
in LTCC currents (ICa,L) with a compensatory increase in
NCX activity. This Ca2 handling phenotype brought about
by GRK2 ablation is resistant to adverse Ca2 handling
remodeling after MI and leads to better cardiac function in
GRK2KO mice post MI.
Methods
Conditional mice bearing floxed GRK2 alleles were described
previously.10,13 G-protein–coupled receptor kinase 2 KO ( myosin
heavy chain  Cre-recombinase  GRK2flox/flox) and wild-type
(WT) (GRK2flox/flox) mice were maintained on a C57BL6 genetic
background. All animal procedures and experiments were performed
in accordance with the guidelines of the Institutional Animal Care
and Use Committee of Thomas Jefferson University. G-protein–
coupled receptor kinase 2 KO and WT mice were 8 to 10 weeks of
age when entering the study. Unstressed normal mice and mice with
coronary artery ligation (myocardial infarction [MI]) or sham oper-
ation were studied. Myocardial infarction was induced by ligating
the left anterior descending coronary artery at 2 to 3 mm below its
origin as described previously,10,14 and animals were studied 28 days
post-MI or sham operation. For the verapamil study, mice were
treated with verapamil starting 14 days after MI or sham operation
until the end of the study period (42 days after MI). Verapamil-
treated mice received oral supplementation of verapamil (Sigma-Al-
drich, St. Louis, MO) as described previously15 and were evaluated
by echocardiography. Cardiac myocytes were isolated cultured from
animals. Myocyte Ca2 transients and contractions, SR Ca2 load,
ICa,L, and NCX-Activity INCX were measured. Quantitative real-time
polymerase chain reaction and Western blot analysis were performed
for gene-expression assessment. Detailed description of experimen-
tal procedures is available in the online-only Data Supplement.
Data are expressed as meanSEM. An unpaired 2-tailed t test or
a 1-way ANOVA and a 2-way ANOVA (linear mixed effects model)
were performed with SAS 9.3 for between-group comparisons,
followed by a posthoc Bonferroni adjustment. For all tests, a P value
0.05 was considered significant.
Results
Myocyte GRK2 Ablation Enhances Adrenergic
Responsiveness of Cellular Contractility and
Ca2 Transients
Our previous study has shown that GRK2 KO mice have
cardiac function comparable to control mice at baseline
(online-only Data Supplement Table 1), but their cardiac
function responds better to -adrenergic stimulation.10 Here,
we determine the cellular mechanisms for this observation.
Myocyte contraction and intracellular Ca2 transients were
recorded from WT and GRK2KO myocytes under baseline
conditions and after AR stimulation. Myocytes from both
lines revealed a similar fractional shortening when paced at
both 0.5Hz and 2Hz (Figure 1A–1C). However, after isopro-
terenol (ISO), myocytes from GRK2KO mice showed a
significantly greater increase in fractional shortening (Figure
1A–1C and online-only Data Supplement Table II). In a good
agreement, as shown in Figure 1D, at baseline, the charac-
teristics and amplitude of the Ca2 transients (as Fura-2
340/380 nm ratio) were similar in both groups of myocytes.
Stimulation with ISO mediated an anticipated increase in the
amplitude of the Fura-2 ratio in WT cardiac myocytes and a
greater increase in GRK2KO cardiac myocytes (Figure 1D–
1F, online-only Data Supplement Table II). We observed no
differences in the Ca2 transient decay time constants at
baseline and after ISO between groups.
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GRK2 Silencing in Myocytes Enhances
ECC Efficiency
Myocyte contractility and Ca2 transients are determined by
Ca2 release from the SR.16 We measured SR Ca2 content
by rapid application of caffeine (caffeine spritz) at baseline or
after ISO stimulation. Figure 2A shows representative trac-
ings of cytosolic Ca2 transients (measured with indo-1 AM)
induced by caffeine spritz after 4 field stimulations in WT and
GRK2KO cardiac myocytes to measure the SR Ca2 load. At
baseline, SR Ca2 load was less in GRK2 myocytes than in
control myocytes (Figure 2B); in response to ISO, the SR
Ca2 load in cardiac myocytes from both WT and GRK2KO
mice was significantly increased, but GRK2KO myocytes
had a greater increase (Figure 2B). Interestingly, a signifi-
cantly higher fractional release of Ca2 was observed in
GRK2KO cardiac myocytes compared with WT myocytes at
both baseline and after ISO (Figure 2C and online-only Data
Supplement Table II).
Figure 1. The loss of GRK2 in myocytes enhances the responsiveness of myocyte contraction and Ca2 transients to AR stimulation.
A, Representative tracings of single myocyte contractions under basal conditions and stimulation with isoproterenol at 0.5 Hz. Aver-
aged myocyte fractional shortening at 0.5 Hz (B) and 2.0 Hz (C) stimulation frequencies under basal conditions and stimulation with
isoproterenol. D, Representative intracellular Ca2 transients measured with Fura-2 (340/380 nm ratio) under basal conditions and stim-
ulation with isoproterenol at 0.5 Hz from the same cell as in A. Averaged Fura-2 ratio amplitude at 0.5 Hz (E) and 2.0 Hz (F) stimulation
frequencies under basal conditions and isoproterenol. For measurements represented by B, C, E and F, a total of 48 to 63 cardiac
myocytes from 3 different hearts were measured for each group; 2-way ANOVA was used for B, C, E, and F. WT indicates wild type;
GRK2KO, G-protein–coupled receptor kinase 2 knockout; and Iso, isoproterenol.
2110 Circulation May 1, 2012
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Loss of Myocyte GRK2 Enhances ICa,L by a Local
Protein Kinase A–Dependent Mechanism but
Blunts Its AR Responsiveness
To explore the underlying cellular mechanisms for the re-
duced SR Ca2 content with enhanced EC coupling effi-
ciency in GRK2 KO myocytes, we measured the ICa,L in
GRK2KO and control myocytes because ICa,L serves as both
the trigger of Ca2 release from the SR and the source for
loading the SR.16 Peak ICa,L density at baseline was
significantly greater in GRK2KO compared with WT
cardiac myocytes (Figure 3A and 3B and online-only Data
Supplement Table II). When stimulated with a saturating
dose of ISO (106 M), peak ICa,L was increased to the same
level in cardiac myocytes from both mouse lines (Figure
3A and 3B), suggesting that the LTCC density was similar
in both groups.4 The voltage dependency of channel
activation was shifted to more negative voltages in
GRK2KO myocytes at baseline, and ISO stimulation
caused a significant leftward shift of activation in WT
myocytes but not in GRK2KO myocytes (Figure 3C and
3D). These results imply that the LTCC in GRK2KO
myocytes could be in such a high activity state that it loses
responsiveness to -adrenergic stimulation.
To explore the underlying mechanisms for these changes
of ICa,L properties, we tested whether the increased ICa,L was
due to increased available channels on the surface membrane,
the increase of channel activities at single-channel levels, or
both. Charge movement was used to quantify the number of
available channels on the surface membrane of KO and
control WT myocytes. Figure 3E shows that there was no
significant difference in the charge movements of the LTCC
induced by various depolarizing voltages, a result which
indicates that there was no significant alteration of LTCC
density on the membrane and that the increased whole-cell
ICa,L could be due to the increased single-channel activities.
Immunoprecipitation of 1c, the pore-forming subunit of the
LTCC, from the same amount of proteins in GRK2KO and
control hearts showed no difference in 1c expression (Fig-
ure 3N). These data suggest that the LTCC in GRK2KO
myocytes must have higher than normal activity, a result
supported by single-channel recording of LTCC activities
(Figure 3J–3M). The availability (Figure 3K) and the open
probabilities (Figure 3L and 3M) were significantly increased
in GRK2KO myocytes, a result that could fully explain the
increase in whole-cell ICa,L in KO myocytes.
Enhanced phosphorylation of the LTCC by protein kinase
A (PKA) may result in increased LTCC activity.4,17 Previ-
ously, we have shown that ARs carry constitutive activation
to activate PKA locally to phosphorylate the LTCC.18 Here,
we tested whether high LTCC activity was mediated by a
PKA-dependent mechanism. H89, a PKA-specific inhibitor,
was used, and it normalized the current density and voltage-
dependent activation of the LTCC in KO myocytes but had
no significant effect on LTCCs in WT myocytes (Figure
3F–3I). The single-channel study further confirmed that the
heightened LTCC activity in the KO myocytes was due to
PKA activation because H89 also normalized the increased
channel activity in KO myocytes (Figure 3J–3M). The
phosphorylation of 1c at Ser1928, a PKA site, was shown to
be greater in GRK2KO hearts than in control hearts (Figure
3N and 3O).
Loss of GRK2 in Myocytes Increases
Na/Ca2-Exchanger Expression
Because there is a decreased SR Ca2 content with
increased ICa,L in GRK2KO myocytes, there should be
increased Ca2 efflux out of GRK2KO myocytes. In
ventricular myocytes, the major route of Ca2 efflux is
through the NCX. One way to measure NCX activity is to
examine the decay rate of caffeine-induced Ca2 transients
that can be fit by a single exponential decay equation.19
The tau value was significantly smaller in the GRK2KO
myocytes than in control myocytes, and ISO did not
change these values (Figure 4A), suggesting that the NCX
Figure 2. GRK2 silencing in cardiac
myocytes alters SR Ca2 content and its
regulation. A, Representative tracings of
the caffeine-induced intracellular Ca2
transients determined with Indo-1 in a
control myocyte and a GRK2KO myo-
cyte. B, Caffeine-induced peak intracel-
lular Ca2 amplitudes under baseline
conditions and isoproterenol stimulation.
C, Fractional release calculated as the
ratio of peak Ca2 concentration
induced by field stimulation to peak
Ca2 concentration induced by caffeine.
For measurements represented by fig-
ures B through C, a total of 16 to 29
cardiac myocytes from 3 different hearts
were analyzed per group; 2-way ANOVA
with posthoc Student t test for B and C.
WT indicates wild type; GRK2KO, G-pro-
tein–coupled receptor kinase 2 knock-
out; NLC, non littermate control; KO,
knockout; and ISO, isoproterenol.
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activity at baseline is increased in GRK2KO myocytes
compared with WT myocytes, a result that was confirmed
by direct measurement of NCX current (Figure 4B) and
NCX protein expression (Figure 4C and 4D).
Loss of GRK2 From Myocytes Decreases Basal
PLB Phosphorylation but Increases Its
Responsiveness to AR Stimulation
The loading of the SR with Ca2 depends on the competition
between the extrusion of Ca2 out of the cell (mainly through
NCX) and the resequestration of Ca2 into SR by SERCA,
which is regulated by PLB.16 Dephosphorylated PLB exerts a
tonic inhibition on SERCA activity. For these reasons, we
determined the expression level of SERCA and PLB as well
as the phosphorylation level of PLB. The expression of
SERCA and PLB was not significantly altered by silencing
GRK2 (Figure 4E–4H). However, the phosphorylation of
PLB at Ser16, a PKA site, was significantly reduced in
GRK2KO hearts but the phosphorylation of PLB at Thr17
site was not altered (Figure 4G and 4H). When myocytes
were stimulated with the AR agonist ISO, a robust increase
in the phosphorylation of PLB at Ser16 sites was observed in
both WT and GRK2KO cardiac myocytes (Figure 4I and 4J).
However, a significant leftward shift of the dose–response
curve was found in GRK2KO myocytes compared with WT
cells (Figure 4J), demonstrating higher AR sensitivity in
cells isolated from unstressed GRK2KO mice.
To further clarify the mechanism responsible for the
hypophosphorylation of PLB, we examined whether phos-
phodiesterase 4 (PDE4), which is activated by PKA, could
Figure 3. G-protein–coupled receptor kinase 2 silencing in myocytes increases basal ICa,L by enhancing PKA-dependent augmentation
of LTCC channel activity but reduces its responsiveness to -adrenergic stimulation. A, Current–voltage relationships of ICa,L (pA/pF)
under basal conditions and isoproterenol stimulation. B, Peak ICa,L under basal conditions and isoproterenol stimulation. C, Voltage
dependence of ICa,L activation at basal conditions and under isoproterenol stimulation. D, Voltage potentials at 50% ICa,L activation in
WT and KO myocytes before and after ISO. E, Charge movement measurements in control and KO myocytes at baseline showing no
difference in available LTCCs on the surface membrane in KO and WT myocytes. F, The effect of H89 on the current–voltage relation-
ships of ICa,L in sham WT control and KO myocytes. H89 significantly decreased ICa,L at most tested voltages in KO myocytes but not
in WT myocytes. G, Effects of H89 on maximum ICa,L in WT and KO myocytes. H and I, Effects of H89 on V0.5 of ICa,L activation in WT
and KO myocytes. J, Examples of single-channel recordings of the LTCC in KO and WT myocytes before and after treatment with H89.
Sweeps were selected in an increment of 20 (ie, the sweeps shown were sweep 1, 20, 40, etc.). The downward deflections were the
openings of the channel. At the bottom of the raw sweeps were the ensemble average current of all 400 sweeps recorded. The avail-
ability (K), open probability in active sweeps (L), and the overall open probability (NPo, shown in M) were significantly increased in KO
myocytes but were normalized by H89. H89 did not have significant effects on these parameters of single LTCC activities in WT myo-
cytes. N, Western blot of immunoprecipated total 1c and phosphorylated 1c at ser1928. O, Phosphorylation level of 1c in
unstressed WT and GRK2KO hearts. n5 animals/group; 2-way ANOVA with posthoc t test was used for comparison for A through M
in this Figure; t test was used for O. ICa,L indicates L-type Ca
2 channel currents; WT, wild type; GRK2KO, G-protein–coupled receptor
kinase 2 knockout; ISO, isoproterenol; Gca, Voltage dependence of ICaL activation; and H89, PKA inhibitor.
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play a mechanistic role. A PDE4-specific inhibitor, rolipram
(10 mg/kg BW, i.p.), was injected into unstressed WT and
GRK2KO mice for 2 hours to allow it to take effect. Then the
hearts were snap frozen in liquid nitrogen, and Western
blotting for phospho-PLB and total PLB was performed.
Interestingly, rolipram blunted the hypophosphorylation of
PLB in GRK2KO myocytes (Figure 4K and 4L), which
indicates that the proposed higher PKA activity in GRK2KO
myocytes results in an increased local PDE4 activity causing
hypophosphorylation of PLB.
Loss of Myocyte GRK2 Before MI Prevents the
Development of Heart Failure and Preserves
Contractility of Myocytes
Our previous studies have shown that cardiac specific loss of
GRK2 ameliorates the development of HF after MI.10 In vivo
cardiac function as assessed by echocardiography 28 days
after MI showed that although sham GRK2KO mice were
indistinguishable from sham WT mice, GRK2KO mice had
significantly improved post-MI cardiac function and ventric-
ular remodeling after the loss of myocyte GRK2 (online-only
Data Supplement Table I). Because this improved post-MI
cardiac function was seen in GRK2KO mice with similar
infarct sizes, the beneficial effects of GRK2 deficiency
probably occurs at the myocyte level. Therefore, the function
of cardiac myocytes isolated from WT and GRK2KO mice at
28 days after MI was determined. The basal fractional
shortening and Ca2 transient amplitudes in myocytes from
GRK2KO mice after MI (GRK2KO MI) were almost normal
compared with GRK2KO myocytes from mice not subject to
MI and greater than those of WT cardiac myocytes after MI
(WT MI) at both pacing frequencies of 0.5Hz and 2Hz
(Figure 5A, B, D and E and online-only Data Supplement
Table II). Furthermore, WT MI myocytes had a blunted
functional response to ISO. In contrast, cardiac myocytes
from GRK2KO mice after MI displayed significantly im-
proved -adrenergic responses (Figure 5A, B, D, and E).
These results clearly show that the loss of GRK2 in cardiac
myocytes can partially prevent pathological cellular mechan-
ical and Ca2-handling remodeling after MI and provide a
potential cellular mechanism for the benefits of GRK2
lowering or inhibition in the failing heart.
Figure 4. Silencing of GRK2 in cardiac myocytes increased NCX expression, reduced PLB phosphorylation by PKA-dependent PDE4
activation, and enhanced responsiveness to ISO. A, Tau values of caffeine-induced intracellular Ca2 transient decay, indicating
increased NCX activity in GRK2KO myocytes; n16 to 29 cardiac myocytes from 3 different hearts. B, NCX currents at baseline in con-
trol (WT) and GRK2KO myocytes; n4 animals/group, 2-way repeated ANOVA with posthoc Student t test. C, Western blot of NCX
proteins in WT and GRK2KO hearts. D, NCX expression normalized to GAPDH. E and F, SERCA expression in WT and GRK2KO
hearts. G and H, PLB expression and phosphorylation at Ser16 (PKA site) and Thr17 (CaMK II site) in WT and GRK2KO hearts; n5
animals/group D, F, and H; t test for D, F, and H. I and J, PLB phosphorylation at Ser16 in response to different concentrations of ISO;
n5 animals/group; data were analyzed by regression with repeated measures for J. K and L, Western blotting for pSer16-PLB and
total PLB in WT and GRK2KO hearts stimulated with or without the selective PDE4 inhibitor rolipram; a total of 3 to 5 hearts were ana-
lyzed for each group; 1-way ANOVA for L. WT indicates wild type; KO, knockout; ISO, isoproterenol; INCX, NaCa
2 exchange cur-
rent; NCX1, NaCa2 exchange 1; SERCA, sarcoplasmic/endoplasmic reticulum Ca2 ATpase; PLB, phospholamban; PLBt, total
Phospholamban; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; and N.S., not significant.
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GRK2KO MI Myocytes Have Preserved SR Ca2
Loading and ICa,L
A decrease in the SR Ca2 load is a contributing factor for
depressed myocyte contractility, a hallmark of HF. Although
GRK2KO mice without MI having a lower SR Ca2 load
than WT mice without MI, the SR Ca2 load in GRK2KO MI
myocytes was not decreased as in WT MI myocytes (Figure
6A and B and online-only Data Supplement Table II).
Fractional Ca2 release from the SR was higher in GRK2KO
MI myocytes as well, explaining the preserved myocyte
contractility (Figure 6C). NaCa2 exchanger activity, as
indirectly assessed by the decay constant tau of the caffeine-
induced Ca2 transient was normalized in post-MI GRK2KO
myocytes, despite significant increases in NCX activity in
infarcted WT mice consistent with severe HF (Figure 6D).
Improvements in intracellular Ca2 transients and SR
fractional Ca2 release in the GRK2KO MI myocytes could
result from changes in cardiac myocyte ICa,L. Although basal
ICa,L amplitudes in both post-MI WT and GRK2KO myocytes
were reduced compared with pre-MI values (see Figure 3A
and 3B), peak ICa,L in post-MI myocytes were significantly
greater with the loss of GRK2 (Figure 6E and online-only
Data Supplement Table II). When stimulated with ISO
(106 M), ICa,L in GRK2KO post-MI myocytes was only
insignificantly increased (12.96.9%, n4), but ICa,L in
post-MI WT myocytes was significantly increased by
84.318.1% (n7) (Figure 6F). However, after ISO, ICa,L
amplitudes in myocytes were not different between the 2
mouse lines (Figure 6G and 6H), indicating similar LTCC
density. The marked enhancement in basal ICa,L in the
GRK2KO MI myocytes might contribute to the normalization
of intracellular Ca2 handling and improved cardiac myocyte
contractility. Of interest, the ISO stimulation caused a signif-
icant leftward shift of voltage dependency of channel activa-
tion in WT post-MI myocytes but not in GRK2KO myocytes,
probably because the activation of ICa,L in GRK2KO MI
myocytes at baseline was already shifted to the left. After ISO
stimulation, the voltage-dependent activation of ICa,L was
similar in both groups (Figure 6G and 6H).
Loss of Myocyte GRK2 Inhibits Adverse Cellular
Remodeling Post-MI
Cardiac myocyte size at 28 days post-MI was assessed by
measurements of myocyte capacitance. Myocytes isolated
from GRK2KO MI mice had significantly smaller capaci-
tance, indicating less myocyte hypertrophy and inhibition of
adverse cellular remodeling compared with WT mice post-MI
(GRK2KO MI 21119pF versus WT MI 31135pF versus
WT Sham 17819pF versus KO Sham 18815pF; P0.05
between GRK2KO MI and WT MI).
Figure 5. Loss of GRK2 in cardiac myocytes ameliorates single-cell contractility and Ca2 handling post-MI. Measurements were
obtained at 0.5Hz (A–C) or 2Hz (D–F) under basal conditions and isoproterenol stimulation (108 mol/L). Fractional shortenings (A and
D), Fura-2 ratio amplitudes (B and E) representing the change of intracellular Ca2 transient from baseline, and tau of Ca2 transient
decay (C and F) were shown. For all measurements, a total of 60 cardiac myocytes from 6 different hearts were measured for each
group; 2-way ANOVA. Iso indicates isoproterenol; MI, myocardial infarction; WT, wild type; and GRK2KO, G-protein–coupled receptor
kinase 2 knockout.
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Beneficial Effects of Myocyte GRK2 Silencing Is
Suppressed by the LTCC Blocker Verapamil
To determine if the beneficial Ca2 effects seen post-MI after
myocyte GRK2 lowering is mediated through the novel
changes in LTCC function, we treated WT and GRK2KO
mice with verapamil from 14 days till 42 days post-MI.
Interestingly, echocardiography revealed that verapamil treat-
ment negated some of the beneficial effects of GRK2 silenc-
ing on post-MI cardiac function whereas the LTCC blocker
had minimal effects on post-MI WT mice (Figure 7A).
Furthermore, cardiac brain natriuretic peptide messenger
RNA expression as a molecular marker of HF was signifi-
cantly lower in post-MI GRK2KO mice compared with WT
MI mice but was reversed by verapamil treatment to the level
seen in post-MI WT mice (Figure 7C). It could be true that
the absolute amount of Ca2 current blocked by verapamil is
more in GRK2 KO myocytes because the total LTCC density
is higher in GRK2 KO MI myocytes, and thus verapamil had
a stronger effect in KO MI myocytes. In conclusion, it
appears that the beneficial effects offered by a loss of GRK2
in cardiomyocytes are at least in part attributable to the
upregulation of ICa,L.
Discussion
G-protein–coupled receptor kinase 2 is an important mole-
cule in the heart. It is not only a primary regulator of
adrenergic signaling but also claims an important role in the
development of HF.8–10 It is upregulated during the early
stage in injured myocardium, indicating that it participates in
the progression of ventricular dysfunction and cardiomyopa-
thy.8–10 Our previous studies have shown that GRK2 silenc-
ing10 or inhibition by ARKct20 is able to improve cardiac
function during HF progression after MI. However, the
specific role of GRK2 in the regulation of normal and failing
Ca2 cycling has never been studied. In HF, myocyte Ca2
cycling is deranged, and abnormalities include altered cardiac
LTCC density and properties and reduced SR Ca2 content
due to decreased SERCA and increased NCX activities.
These changes result in reduced intracellular Ca2 transients
and depressed myocyte contractility.1,4 Our current study has
revealed that GRK2 can influence myocyte Ca2 homeostasis
and that its absence in cardiac myocytes10,13 causes a novel
Ca2 handling phenotype that is resistant to cardiac function
deterioration after MI. The benefits rendered by GRK2
silencing are associated with the differential regulation of
sarcolemmal and SR Ca2 handling by the -adrenergic
system.
A Novel Ca2-Handling Phenotype Induced by
GRK2 Silencing
Although GRK2 plays an important role in regulating the
-adrenergic system, its loss does not affect basal cardiac10
and cardiomyocyte function. Myocyte loss of GRK2 did not
change characteristics of basal intracellular Ca2 transients
and myocyte contractions. However, detailed characterization
of myocyte Ca2 handling has shown many differences in EC
coupling between GRK2KO and WT myocytes: (1) The SR
Ca2 content is reduced in GRK2 KO myocytes, but Ca2
Figure 6. Myocyte GRK2 silencing inhibits adverse Ca2-handling remodeling post-MI. A, Representative tracings of the caffeine-
induced intracellular Ca2 transients determined with Indo-1; B, Amplitudes of Ca2 transients elicited by field stimulation (0.5 Hz) and
caffeine spritz; C, Fractional release calculated as the ratio of peak Ca2 concentration induced by field stimulation to peak Ca2 con-
centration induced by caffeine; D, Tau of caffeine-induced intracellular Ca2 transients. n14 to 23 cells from 4 to 5 animals/group,
unpaired 2-tailed t test for B, 2-way ANOVA for C and D; E, Current–voltage relationship of ICa,L (pA/pF) under basal conditions and
isoproterenol stimulation in post-MI WT and KO myocytes; F, Percentage increase in peak ICa,L by isoproterenol. G, Voltage depen-
dence (G-V curve) of ICa,L activation at basal conditions and under isoproterenol stimulation. H, Voltages at 50% ICa,L activation; n7
cells from 3 to 4 different animals/group; 1-way ANOVA for E through H. MI indicates myocardial infarction; WT, wild type; GRK2KO,
G-protein–coupled receptor kinase 2 knockout; [Ca2]i, intracellular Calcium; ICa,L, L-type Ca
2 channel currents; ISO, isoproterenol;
Gca, Voltage dependence of ICaL activation; and KO, knockout.
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transients and contraction in GRK2KO myocytes are normal
because of an increased fractional Ca2 release from the SR;
(2) increased ICa,L ensures normal Ca2 transients and cardiac
myocyte contractility; (3) decreased SR Ca2 content in the
face of increased ICa,L is due to increased Ca2 efflux through
the NCX and the inhibition of SERCA by hypophosphory-
lated PLB; and (4) increased ICa,L is possibly due to local
increase in PKA activity. Most of these aspects of Ca2
handling in GRK2KO myocytes, except the greater than
normal ICa,L and enhanced -adrenergic regulation, have
some similarity with those observed in failing myocytes.21
These findings could imply that, even in failing myocytes,
some of the Ca2 handling aspects could be more of
adaptive mechanisms.
Differential Regulation of Sarcolemmal and
SR Ca2 Handling by the -Adrenergic System
Our data clearly show that there is a differential regulation of
the LTCC on the sarcolemma and the PLB on the SR by the
-adrenergic system in GRK2KO myocytes: At baseline, the
LTCC is already in high-activity mode probably because of
the high-phosphorylation state of the channel, but the LTCC
loses its responses to -adrenergic stimulation; in contrast,
the PLB is in a low-phosphorylation state (hypophosphory-
lation), but it has enhanced responsiveness to -adrenergic
receptor (-AR) stimulation. Our study indicates that the
increased LTCC activity could be due to an increase in
subsarcolemmal (local) PKA activation brought about by
constitutive activity of the -ARs. In normal cardiac physi-
ology, GRK2 mediates the desensitization of -ARs.20 The
loss of GRK2 prevents desensitization of -ARs and thus
likely promotes the accumulation of activated -ARs and
causes constitutive activity of -ARs in GRK2KO myocytes
even after the isolation. The increase in LTCC activity
induced by constitutive 1-ARs has been shown in cardiac
1-AR–overexpression mice.18 The high LTCC activity in
GRK2KO myocytes blunts the responsiveness of the channel
to -adrenergic stimulation. Similar situations have been
reported in myocytes with high basal LTCC activities.17,22
Recently, we have shown that overexpression of ARKct, an
inhibitor of GRK2, in adult rat myocytes increases basal ICa,L,
as we have seen with GRK2 silencing. However, ARKct
overexpression also enhanced the responses of ICa,L to ISO,11
which is in contrast to our findings with GRK2KO. These
results suggest that potentially different mechanisms are
involved in our current study and the ARKct study,11 with
the net effect (increased LTCC) being comparable. Primarily,
ARKct reduces the inhibitory effect of the  subunits of
activated heterotrimeric-G proteins (G) on the LTCC
whereas GRK2KO leads to a local increase in PKA, thereby
activating the LTCC. The role of G in this setting was not
specifically addressed, however: If G was released with the
KO of GRK2, the inhibitory effect on the LTCC must be at
least overcome by the PKA-dependent activation of the
LTCC. An interesting experiment for future studies will
indeed be the expression of ARKct in GRK2KO myocytes.
Figure 7. Beneficial effects of myocytes’
GRK2 knockout are reduced by the
LTCC blocker verapamil. Echocardio-
graphic measurements of fractional
shortening (A) and left ventricular end-di-
astolic diameter (B) at 42 days post-MI
or sham operation. Mice were supple-
mented orally with verapamil starting 14
days post-MI until the end of the study
period (42 days post-MI). n6 to 8/sham
group; n15 to 25/MI group without ve-
rapamil; n10 to 13/MI group with ve-
rapamil; 1-way ANOVA. C, Cardiac myo-
cyte brain natriuretic protein messenger
RNA levels 42 days post-MI or sham
operation; n5 to 6/group for sham;
n8 to 9/group for MI; 1-way ANOVA
and unpaired 2-tailed t test. FS indicates
fractional shortening; WT, wild type;
GRK2KO, G-protein–coupled receptor
kinase 2 knockout; MI, myocardial
infarction; EDD, end-diastolic diameter;
BNP, brain natriuretic protein; and
mRNA, messenger RNA.
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This experiment will finally address the role of G in this
setting, but such a goal goes far beyond the scope of our
current study. The use of different models (GRK2KO in mice
in vivo for a relatively long period of time versus ARKct
expression in cultured rat ventricular myocytes11 in vitro for
24 hours) could also account for different mechanisms in
mediating increased basal ICa,L and different degrees of
responsiveness to ISO stimulation.
In contrast to the enhanced LTCC phosphorylation in
GRK2KO myocytes, the phosphorylation state of PLB on the
SR is lower than normal and the responsiveness of PLB to
-adrenergic agonists is enhanced. The underlying mecha-
nism is related to locally activated PDE4 by activated
subsarcolemmal PKA because rolipram, a selective PDE4
inhibitor, blunted the hypophosphorylation of PLB in
GRK2KO hearts. Subsarcolemmal PDEs are generally able to
diffuse to the SR and thus can limit local cAMP production
and PKA activation.23 Our results mechanistically explain the
differential regulation of sarcolemmal versus SR Ca2 han-
dling associated with the cardiac myocyte lowering of GRK2,
which ultimately can improve cardiac function in HF models.
The Novel Ca2-Handling Phenotype Induced by
the Loss of GRK2 Is Resistant to Adverse
Remodeling in Hearts After MI
As summarized above, GRK2KO induces a novel Ca2-
handling phenotype that maintains a normal myocyte con-
tractility in a way that is less dependent on SR Ca2 but more
dependent on ICa,L. We also show that this type of Ca2
handling in GRK2KO myocytes is more resistant to adverse
remodeling induced by MI in that the SR Ca2 content and its
regulation by the AR system and ICa,L density are better
preserved and NCX activity is not increased. The cellular
processes responsible for better remodeling after MI in
GRK2KO mice are potentially due to a combination of
increased ICa,L and normalized NCX activity resulting in
reduced SR Ca2 content at baseline. We suspect that the
relatively unchanged and small NCX activity after MI pre-
disposes the GRK2KO MI myocyte to maintain an un-
changed SR Ca2 loading, which is in contrast to WT mice.
Overall, this combination renders cardiac myocytes less
susceptible to SR Ca2 overload, which is known to induce
myocyte apoptosis and necrosis.24,25 Importantly, the benefi-
cial effects of GRK2KO are negated by an LTCC antagonist,
verapamil. Elevated SR Ca2 content might also participate
in myocyte hypertrophy.26 In this study, GRK2KO myocytes
develop less cardiac myocyte hypertrophy post-MI. This
could be due to the concomitant decrease of SR Ca2 load
induced by the loss of GRK2 expression in the cardiac
myocyte. The enhanced -adrenergic responsiveness in
GRK2KO myocytes may also contribute to the beneficial
effects of GRK2 silencing.
The results obtained here explain our previous studies
showing that the loss of GRK2 in cardiac myocytes reduces
HF-associated mortality and enhances global cardiac function
post-MI.10 The improvements associated with the loss of
GRK2 expression and activity are in large part attributable to
the normalization of intracellular Ca2 cycling and cardiac
myocyte function.
Conclusions
In summary, our data provide novel and important insights
into the role of GRK2 in normal and failing hearts. Loss of
GRK2 in cardiac myocytes enhances ECC efficiency in the
presence of a lower than normal SR Ca2 loading condition
and better -adrenergic responsiveness in unstressed hearts.
This enhancement of ECC occurs through differential regu-
lation of sarcolemmal versus SR Ca2 handling, with the net
result being improved Ca2 transients leading to the amelio-
ration of the HF phenotype. This is seen at the myocyte level
and also globally in vivo with improved cardiac function of
GRK2KO mice post-MI. Our data revealed for the first time
that the beneficial effects seen with a loss of myocyte GRK2
activity after MI were associated with marked amelioration of
cardiac myocyte contractility and significant improvements
in intracellular Ca2 cycling effected by modulation of ICa,L.
These effects seen at the myocyte level may also contribute
to the beneficial effects seen in various HF models treated
with the ARKct peptide as a GRK2 inhibitor.8,9,12 Further,
GRK2 appears to induce novel regulatory modulation in the
LTCC because currents were enhanced with a loss of GRK2.
Overall, our current results mechanistically explain the ben-
eficial effects of GRK2 silencing or inhibition after MI in the
heart at the cellular and molecular levels and validates GRK2
as a potential target for HF prevention and treatment.
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CLINICAL PERSPECTIVE
G-protein–coupled receptor kinase 2 (GRK2) is a molecular culprit in the development and progression of heart failure
(HF). We now provide the molecular basis for potential benefits of therapeutic strategies aiming at GRK2 inhibition. With
our current study we demonstrate that loss of GRK2 in cardiac myocytes enhances excitation-contraction coupling in
unstressed hearts and in failing myocytes. We show that this enhancement of excitation-contraction coupling occurs
through differential regulation of sarcolemmal versus sarcoplasmic reticulum Ca2 handling, with the net result being
improved Ca2 transients without sarcoplasmic reticulum Ca2 overload leading to reversal of the HF phenotype. Further,
we demonstrate that the beneficial effects seen with GRK2 inhibition in HF were associated with marked amelioration of
cardiac myocyte contractility and significant improvements in intracellular Ca2 cycling effected by modulation of the
cardiac L-type Ca2 channels. A clearly novel finding is the compartmentalization of intracellular signaling by GRK2 and
thereby differential regulation of Ca2 signaling. Overall, our current results explain the beneficial effects of GRK2
knockout in cardiac myocytes with intracellular changes in Ca2 cycling being orchestrated to improve overall
cardiac-myocyte contractility. Furthermore, our study demonstrates that this interplay between GRK2 and the L-type Ca2
channels might represent an attractive target to correct deranged Ca2 cycling in the failing heart. Future gene therapies
or pharmacological strategies will thus potentially directly target this interplay and might thus contribute to further
improvements in clinical HF treatment.
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SUPPLEMENTAL MATERIAL 
 
SUPPLEMENTAL METHODS 
Experimental animals 
Conditional mice bearing floxed GRK2 alleles were described previously1, 2.  GRK2KO 
(αMHC-Cre x GRK2fl/fl) and WT (GRK2fl/fl) mice were maintained on a C57BL6 genetic 
background. All animal procedures and experiments were performed in accordance with the 
guidelines of the IACUC of Thomas Jefferson University. 
 
Experimental protocols 
GRK2KO and WT mice were 8-10 weeks of age when entering the current study. Unstressed 
normal mice and mice with coronary artery ligation (myocardial infarction (MI)) or sham-
operation were studied. MI was induced by ligation of the LAD 2-3 mm below its origin as 
described previously 2, 3 and animals were studied 28 days post-MI. Sham animals 
underwent operation without ligation of the LAD.  For the verapamil study mice were treated 
with verapamil starting 14 days post MI or sham operation until the end of the study period 
(42 days post MI). Verapamil treated mice received oral supplementation of verapamil 
(Sigma-Aldrich, St. Louis, Missouri, USA) in their drinking water. Verapamil was dissolved in 
10% dextrose solution at a concentration of 1 mg/ml as described previously 4. 
 
Isolation of cardiac myocytes and maintenance of primary cultures  
Adult mouse cardiac myocytes were isolated as previously described5. For Ca2+ transients 
and single myocyte contractility measurements, cells were used within 8 hours after isolation. 
For in vitro cell culture assays, freshly isolated cells were washed and resuspended with α-
MEM (Gibco, Invitrogen Corporation, Carlsbad, California, USA) supplemented with Hanks’ 
salt, and then plated onto laminin (Invitrogen Corporation, Carlsbad, California, USA) pre-
coated culture dishes. Cells were maintained in α-MEM with Hank’s salt solution 
supplemented with L-Glutamine (10 mmol/l), 2, 3-Butandionemonoxime (BDM, 10mmol/l) 
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(Sigma-Aldrich, St. Louis, Missouri, USA) and Insulin-Transferrin-Selenium (1:1000 dilution) 
(Gibco, Invitrogen Corporation, Carlsbad, California, USA) with a humidified atmosphere 
containing 2% CO2 for 24 hours. 
 
For each experiment involving isolated cells cardiac myocytes from one GRK2KO and one 
WT mouse were isolated at the same time and analyzed in parallel. The numbers are 
mentioned in each figure legend; an equal number of cells per animal were analysed from an 
equal number of animals per group. 
 
Ca2+ Transients and single myocyte contractility studies 
Freshly isolated cells were kept in BDM-free tyrodes solution containing 1mM CaCl2. The 
cells were loaded for 10 min with Fura-2 (TefLabs, Austin, Texas, USA), thoroughly washed 
and placed on a laminin coated object slide. The cells were stimulated in an electrical field 
and continuously perfused with tyrodes containing 1mM CaCl2 without (baseline) and with 10-
8M Isoproterenol (Sigma-Aldrich, St. Louis, Missouri, USA). Ca2+ transients were determined 
by recording the Fura2-ratio (340/380nm) (Fluorescence and Contractility System, IonOptix, 
Milton, Massachusetts, USA). Single-cell contractions were measured by video edge 
detection (Fluorescence and Contractility System, IonOptix, Milton, Massachusetts, USA). 
 
Measurement of SR Ca2+ load 
Myocytes were placed in a chamber mounted on an inverted Nikon microscope and perfused 
with normal physiological solution (Tyrode) containing 1mM Ca2+. Since MI may cause the 
increase of diastolic intracellular Ca2+, Indo-1 AM was used to measure Ca2+ transients and 
caffeine-induced Ca2+ transients for myocytes isolated from sham and post-MI hearts as 
described previously 6-8. To assess SR Ca2+ content, 10mM caffeine (Sigma-Aldrich, St. 
Louis, Missouri, USA) was applied on cells for 10 seconds after 4 field stimulations to reach 
steady state. The peak of caffeine-induced Ca2+ transient was used as the index of SR 
content. Peak Ca2+ concentrations of Ca2+ transients induced by field stimulation and caffeine 
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spritz were calculated as follows 9: [Ca2+]i=Kd*R/((Kd/[Ca2+]rest)+1-R), where R is the ratio of 
emitted fluorescence to the resting emitting fluorescence. [Ca2+]rest was considered as 100nM 
and Kd was 1100nM.The ratio of peak Ca2+ concentration induced by stimulation to peak 
Ca2+ concentration induced by caffeine was used as the index of fractional release.  
 
Electrophysiology 
Whole cell L-type Ca2+ channel current (ICa,L) was measured in Na+- and K+-free solutions at 
37°C using techniques described in detail previously.  
	  
Single L-type Ca2+ channel currents were recorded in cell-attached patches with an 
Axopatch 200B amplifier and Clampex 10. The holding potential was -90mV assuming the 
intracellular resting membrane potential was about -70mV (the averaged resting membrane 
potentials in control and DTG myocytes during electrophysiological measurements) and 
depolarized to 10mV. The recording glass pipette contained (in mM): BaCl2, 70; Sucrose, 70; 
NMDG, 10; HEPES, 10; TEA-Cl (tetraammonium chloride), 10; tetrodotoxin (TTX), 0.05; and 
4-Aminopyridine (4-AP), 5; pH7.4 with TEA-OH. The bath solution was normal Tyrode 
solution containing (in mM): NaCl 150, KCl 5.4, MgCl2 1.2, HEPES 5, Glucose 10, Na-
pyruvate 2, CaCl2 1, pH to 7.4 with NaOH. After 400 continuous sweeps of recording at 
0.5Hz, the external solution was changed to a H89 (5µM) containing bath solution and 15 
minutes were waited to allow H89 to fully take effect. Then, another 400 continuous sweeps 
of recording were made. Single-channel and whole-cell Ca2+ currents were analyzed with 
Clampfit 10. To quantify the amount of LTCCs on the surface membrane of the myocytes, 
charege movement measurements of the LTCC were done with pCLAMP10 and an Axon 
200B amplifier as described previously10. Only myocytes with minimal (<10%) rundown of 
ICa,L were included in the data sets. ICa,L was measured at baseline and under stimulation with 
10-6M Isoproterenol. To study the effect of H89 (a PKA inhibitor, Sigma-Aldrich, 5µM) on ICa,L, 
5µM H89 was included with the pipette solution for 10 minutes to allow adequate diffusion of 
H89 into the cell to inhibit PKA.  
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Sodium-calcium exchange current (INCX) was recorded as described previously11. The 
myocyte was bathed in a K+-free solution containing (in mmol/L): NaCl 145, MgCl2 1, HEPES 
5, CaCl2 2, CsCl 5, glucose 10, ouabain 0.02, nifedipine, 0.01, pH 7.4 adjusted with NaOH. 
The internal solution contained (in mM): CsCl 65, NaCl 20, Na2ATP 5, CaCl2 6, MgCl2 4, 
HEPES 10, TEA-Cl 20, EGTA 21, ryanodine 0.0005, pH 7.2 with CsOH. The cell was 
dialyzed for 10 minutes after rupturing the patch and the membrane current was recorded 
with a ramp test (+80mV to -80mV at 100mV/s) following a 100-ms depolarization to +80 
from the holding potential of -40mV. During the recording, the bath solution then was 
changed to the K+-free solution with 5mmol/L Ni2+. Recording was stopped once a stable 
effect of Ni2+ was seen and the Ni2+-sensitive current was INCX. 
 
RNA isolation, reverse transcription and quantitative real-time PCR 
RNA was isolated from snap-frozen samples of the remote zone collected at 28 days post MI 
or sham operation or from cardiac myocytes isolated at 42 days post MI or sham operation 
(verapamil study) as described previously 2. cDNA was synthesized and expression levels of 
NCX and BNP were analyzed using quantitative Real-Time PCR2; 28S or 18S mRNA levels 
were used for normalization. 
 
Western blot analysis 
Western blotting was performed as described previously 3.  Cardiac protein levels of GRK2 
(sc-562, C-15, Santa Cruz Biotechnology, 1:5,000), SERCA (Clone II-H-11, Sigma-Aldrich, 
St. Louis, Missouri, USA), PLB, pPLB S16, pPLB Thr17 (A010-14, -12, and -13, Badrilla, 
Leeds, United Kingdom), and GAPDH (clone 6C5, Millipore, Billerica, Massachusetts, USA) 
were assessed in cardiac myocyte cellular preparations.  Protein content was quantified with 
the BioRad DC Protein Assay (BioRad Laboratories, Richmond, California, USA).  Protein 
samples were separated by 4-20% SDS-PAGE (Invitrogen Corporation, Carlsbad, California, 
USA), and proteins were transferred to PVDF membrane (Millipore Corporation, Billerica, 
Massachusetts, USA) and probed with the first antibody at 4°C overnight.  The proteins were 
 at Thomas Jefferson Universi on August 30, 2013http://circ.ahajournals.org/Downloaded from 
stained with a corresponding Alexa Fluor 680- (Molecular Probes; 1:10.000) or IRDye 
800CW-coupled (Rockland Inc.; 1:10.000) secondary antibody, followed by visualization of 
the proteins with a LI-COR infrared imager (Odyssey, LI-COR, Lincoln, Nebraska, USA), and 
quantitative densitometric analysis was performed applying Odyssey version 2.0 infrared 
imaging software. α1c immunoprecipitation was performed with the Dynabeads Protein A for 
Immunoprecipitation Kit (Invitrogen Corporation, Carlsbad, California, USA) with 700µg crude 
protein extracted from each frozen heart according to the manufacture’s instruction. The 
antibody against α1c for immunoprecipitation was purchased from Millipore (Billerica, MA, 
USA) and the antibodies for the detection of α1c and p1928 α1c were from NeuroMab 
(Davis, CA, USA). 
 
Determination of PKA/PDE4 dependent hypophosphorylation of PLB following loss of 
GRK2 
A PDE 4 specific inhibitor, rolipram (10mg/kg BW, i.p.) (Sigma-Aldrich, St. Louis, Missouri, 
USA) was injected into WT and GRK2KO mice for 2 hours to allow it to take effect. Then the 
hearts were snap-frozen in liquid nitrogen. Western blotting against PLB and pPLB S16 
(A010-14, and -12, Badrilla, Leeds, United Kingdom) and GAPDH (clone 6C5, Millipore, 
Billerica, Massachusetts, USA)  was performed. 
 
Echocardiographic analysis of cardiac function  
Two-dimensional transthoracic echocardiography was acquired with a 12-MHz probe and a 
Vevo770 imaging system (VisualSonics Inc., Toronto, Ontario, Canada) both in sham and 
infarcted mice as described in details elsewhere 3. LV diameters and contractility (fractional 
shortening, FS% = [(LVEDD -LVESD)/LVEDD) × 100]) were assessed by an M-Mode 
recording in the parasternal short axis view. 
 at Thomas Jefferson Universi on August 30, 2013http://circ.ahajournals.org/Downloaded from 
 Statistical analysis 
Data are expressed as mean±SEM. An unpaired two tailed t-test or a one-way ANOVA and a 
two-way ANOVA (linear mixed effects model) were performed with SAS 9.3 for between-
group comparisons followed by a post-hoc Bonferroni adjustment. For all tests, a P value < 
0.05 was considered significant.  
 
SUPPLEMENTAL RESULTS 
Loss of GRK2 in cardiac myocytes before MI reduced the extent of cardiac dysfunction. To 
study the consequence of GRK2 loss on the development of HF, GRK2KO mice and their 
corresponding littermate controls (WT) were subjected to MI. Infarct size was not different at 
24h post MI in GRK2KO mice as compared to WT mice (data not shown). In vivo cardiac 
function was assessed by echocardiography twenty-eight days after MI. In sham operated 
animals no differences were observed between both groups. As we have recently shown 2 
post-MI cardiac function and ventricular remodeling were significantly improved after the loss 
of myocyte GRK2 despite deterioration of cardiac function in corresponding WT mice (see 
online data supplement, Table 1). 
 
SUPPLEMENTAL TABLES 
 
Sham WT Sham GRK2KO MI WT MI GRK2KO 
Heart Rate  
[beats/min] 471 ±! 22 452 ±! 14 415 ±!9 433 ±! 12 
End-Diastolic Diameter 
[mm] 3,08 ±! 0,12 3,14 ±! 0,16 4,44 ±!0,13 4,03 ±! 0,09 * 
End-Systolic Diameter  
[mm] 1,81 ±! 0,09 1,87 ±! 0,12 3,63 ±!0,13 3,03 ±! 0,09 * 
Fractional Shortening  
[%] 41,41 ±! 1,53 40,60 ±! 1,03 18,21 ±!0,94 24,88 ±! 1,34 * 
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Data supplement table 1: Echocardiography for determination of cardiac function in 
WT and GRK2KO mice with (MI) or without MI (Sham). In vivo cardiac function was 
assessed by echocardiography twenty-eight days after MI. n=10animals/sham group, n=15-
19animals/MI group, *: p<0.05. 
 
 
 
Data supplement table 2: Myocyte properties in WT and GRK2KO myocytes without or 
with MI. Averaged myocyte fractional shortening at 0.5 Hz (FS at 0.5Hz [%]) and 2.0 Hz (FS 
at 2Hz [%]) stimulation frequencies under basal conditions; averaged Fura-2 ratio amplitude 
at 0.5 Hz ([Ca2+]i  peak at 0.5Hz [Fura-2,340/380]) and 2.0 Hz ([Ca2+]i  peak at 2Hz [Fura-
2,340/380]) stimulation frequencies under basal conditions; for these measurements a total 
of 48-63 cardiac myocytes from 3-6 different hearts were measured for each group. Caffeine-
induced peak intracellular Ca2+ amplitudes under baseline conditions (SR Ca2+ load [indo-1, 
410/480]); fractional release calculated as the ratio of peak Ca2+ concentration induced by 
field stimulation to peak Ca2+ concentration induced by caffeine (Fractional Ca2+ release 
[%]); for these measurements a total of 14-29 cardiac myocytes from 3-5 different hearts 
were analyzed per group. Peak ICa,L  (ICa-L peak [pA/pF] ) under basal conditions; 3-5 hearts 
were analyzed for each group. One-way ANOVA. *: p<0.05: GRK2KO sham vs. WT sham, #: 
p<0.05, WT MI vs. WT sham, %: p<0.05, GRK2KO MI vs. WT MI. 
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